New Delhi: Haleon has announced an investment of approximately ₹2,000 crore to establish its first manufacturing facility in India, marking a significant milestone in the company’s long-term growth strategy and commitment to the country.
The state-of-the-art greenfield facility will be developed at Pithampur in Madhya Pradesh and is expected to strengthen Haleon’s local manufacturing capabilities while supporting the Government of India’s ‘Make in India’ vision.
Spread across more than 40 acres within the Smart Industrial Park, the facility represents a major investment in India’s consumer health sector and underscores Haleon’s commitment to delivering better everyday health while positioning India as a strategic growth market.
The announcement was made in the presence of Dr. Mohan Yadav, Chief Minister of Madhya Pradesh; Brian McNamara, Chief Executive Officer, Haleon; Kedar Lele, CEO India and President India Subcontinent, Haleon; and Namrata Patel, Chief Supply Chain Officer, Haleon.
The new manufacturing site will serve as a key enabler for Haleon’s expansion in India by strengthening supply chain resilience, increasing domestic value addition, and supporting exports to wider Asian markets.
Aligned with the Government’s ‘Make in India’ initiative, the investment is expected to generate broad-based economic value over the next decade by enhancing export competitiveness, contributing to state revenues, and integrating India more deeply into global supply chains.
The facility is projected to create up to 500 jobs along with indirect employment opportunities, with a focus on skill development, local talent, and supplier ecosystems.
Haleon also aims to build a diverse and inclusive workforce, with an ambition of up to 30% women employees at the site.
Also Read: GPS Renewables Announces ₹635 Crore Series C Fundraise Led by PixelSky Capital
Speaking on the occasion, Mohan Yadav, Chief Minister of Madhya Pradesh, said: “Madhya Pradesh continues to emerge as a preferred destination for global investment, driven by its robust infrastructure, skilled workforce, and industry-friendly policies. Haleon’s decision to establish its first manufacturing facility in India at Pithampur reflects the growing confidence of leading global companies in the state’s growth potential and business ecosystem.
This ₹2,000 crore investment will further strengthen Madhya Pradesh’s position as a key manufacturing and export hub, while contributing to economic development and industrial advancement. The Government of Madhya Pradesh remains committed to supporting Haleon throughout its growth journey in the state and fostering an enabling environment for sustainable industrial progress.”
Brian McNamara, CEO of Haleon, said: “India is a key strategic market for Haleon and an important driver of our long-term growth. This investment strengthens our local manufacturing footprint and expands our reach in one of the world’s fastest-growing consumer health markets.
By increasing access to our trusted brands and building our capabilities on the ground, we are well positioned to capture the significant opportunities ahead. We aim to expand access to better everyday health for more than 300 million additional consumers in India. This will be key to achieving our broader ambition to reach one billion more consumers globally by 2030.”
Kedar Lele, CEO India and President, Haleon ISC, added: “India is central to Haleon’s growth ambitions, both in South Asia and globally. Our investment in this new site will bring us closer to consumers, strengthen access to our brands, and support sustainable long-term growth.
We are grateful for the strong partnership and support from the Government of Madhya Pradesh and Madhya Pradesh Industrial Development Corporation (MPIDC) in enabling this investment.
As demand for trusted everyday health solutions continues to grow, this facility will enhance our ability to serve consumers across India and global markets, particularly in Oral Health, while reinforcing our commitment to making everyday health more accessible to millions.”
The facility has been designed using Haleon’s new global advanced blueprint and will incorporate future-ready automated manufacturing capabilities.
It is expected to become operational by 2029–30, enabling the company to meet growing domestic and international demand.
Also Read: TIEA Connectors to Commercialize Advanced Airborne and EV Charging Connectors with TDB Support
Rooted in Haleon’s purpose of delivering better everyday health with humanity, the investment further reinforces its commitment to making quality oral health solutions more accessible.
Sensodyne, one of the company’s flagship brands, has played an important role in India’s oral health journey for over a decade by helping millions better understand and manage their oral health needs.
About Haleon India Subcontinent
Haleon is a consumer health company solely focused on better everyday health. Its people, brands, research, investments, and innovation are dedicated to improving consumers’ everyday health outcomes.
In India, the company’s portfolio spans Oral Health, Digestive Health, Pain Relief and Respiratory (PRS), and Vitamins, Minerals and Supplements (VMS), with brands including Sensodyne, Eno, Otrivin, Centrum, Iodex, Crocin, Parodontax, and Ostocalcium.
The total planned investment for the manufacturing facility is approximately £175 million, equivalent to around ₹2,000 crore based on an exchange rate of £1 = ₹115.
